The head of the U.S. Food and Drug Administration’s drug division, Dr. George F. Tidmarsh, resigned on November 2, 2025, one ...

United States real-world studies highlight the importance of controlling lupus nephritis to improve patient prognosis.

The results of the ALLEGORY trial of Gazyva (obinutuzumab) suggest that the anti-CD20 antibody could have broad utility in ...

Lupus nephritis is a serious complication of lupus — and because it doesn’t always cause symptoms right away, it’s important to find it early. Talk to your lupus doctor about getting screened (tested) ...

Greater disease activity and higher proteinuria levels were associated with a greater risk for VTE among patients with LN.

These findings underscore the limitations of relying on proteinuria alone to assess LN treatment success and demonstrate the clinical utility of biomarker-guided risk stratification.

This transcript has been edited for clarity. Matthew A. Sparks, MD: I'm Dr Matthew Sparks, and welcome to Medscape's InDiscussion podcast series on chronic kidney disease. Today we'll be discussing ...

The FDA has approved Gazyva (obinutuzumab) for the treatment of adult patients with active lupus nephritis who are receiving standard therapy.

AJMC ®: What measures can be taken to enhance comprehensive screening efforts for the early diagnosis of lupus nephritis in patients who have systemic lupus erythematosus? How do you screen for lupus ...

The FDA has approved Gazyva (obinutuzumab) for treating adult patients with active lupus nephritis who are already on ...

Phase III ALLEGORY study met primary and all key secondary endpoints with Gazyva/Gazyvaro, an anti-CD20 monoclonal antibody ...